Suzano (SUZB3) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
16 Jul, 2026Executive summary
Achieved record sales volumes in pulp (12.5 million tons) and paper/packaging (1.5 million tons) for 2025, with strong year-over-year growth and operational excellence across key regions.
Net sales reached R$50.1 billion in 2025, up 5.7% year-over-year, with net income of R$13.4 billion, reflecting a return to profitability.
Major acquisition announced: 51% stake in a global tissue business from Kimberly-Clark for US$1.73 billion, expected to close in mid-2026, supporting international expansion.
Operational efficiencies and the Ribas do Rio Pardo operation contributed to the lowest cash production cost since 2021, supporting competitiveness.
Demonstrated resilience and competitiveness with strong operational and free cash flow despite a low price cycle.
Financial highlights
Adjusted EBITDA for 2025 was R$21.7 billion, with a margin of 43.4%, and free cash flow reached $400 million in Q4 2025.
Net debt decreased to US$12.6 billion, leverage at 3.2x by end of 2025, and liquidity increased to US$6.6 billion.
Net income was R$13.4 billion, rebounding from a loss in 2024.
Gross profit was R$16.2 billion, with cash and equivalents rising to R$15.2 billion.
EBITDA margin for pulp remained robust at 50% for 2025.
Outlook and guidance
2026 cash production cost of pulp projected to remain broadly in line with Q4 2025 levels, with further cost improvements expected.
Management approved a 2026 capital budget of R$10.9 billion, with reduced CAPEX guidance and focus on operational efficiency.
Maintenance downtimes in Q1 and Q2 2026 will constrain pulp availability and require inventory buildup.
Kimberly-Clark JV and tissue acquisition expected to close mid-2026, expanding global reach.
New revolving credit facility of US$1.78 billion arranged in February 2026 to enhance liquidity.
Latest events from Suzano
- Pulp sales and prices up YoY, but profit and EBITDA fell; major tissue deal to close mid-2026.SUZB3
Q1 202616 Jul 2026 - Strong sales growth, robust cash flow, and major strategic moves marked the quarter.SUZB3
Q2 202510 Jul 2026 - Adjusted EBITDA dropped 20% YoY to R$5.2bn as lower pulp prices offset efficiency gains.SUZB3
Q3 202510 Jul 2026 - Net income surged to R$6.3B in 1Q25, driven by strong sales, FX gains, and cost discipline.SUZB3
Q1 202510 Jul 2026 - EBITDA up 60% YoY to R$6.3B, but net loss of R$3.8B on FX and derivative impacts.SUZB3
Q2 202410 Jul 2026 - Net revenue and EBITDA surged on higher sales and FX gains, with leverage and liquidity improving.SUZB3
Q3 202410 Jul 2026 - Record sales and EBITDA growth from new mill and acquisitions, despite net loss on FX impacts.SUZB3
Q4 20248 Jul 2026 - Strong financials, cost discipline, and sustainability drive growth and diversification.SUZB3
Conference presentation25 Jun 2026 - Strong financial performance, disciplined growth, and ESG leadership drive value creation.SUZB3
Investor presentation23 Jun 2026